|
Volumn 2 Suppl 1, Issue , 2001, Pages
|
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
TAXOID;
TRASTUZUMAB;
ADJUVANT CHEMOTHERAPY;
BIOSYNTHESIS;
BREAST TUMOR;
CLINICAL TRIAL;
FEMALE;
FLUORESCENCE IN SITU HYBRIDIZATION;
HUMAN;
REVIEW;
SURVIVAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS;
FEMALE;
HUMANS;
IN SITU HYBRIDIZATION, FLUORESCENCE;
RECEPTOR, ERBB-2;
SURVIVAL ANALYSIS;
TAXOIDS;
MLCS;
MLOWN;
|
EID: 0009936828
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2001.s.003 Document Type: Review |
Times cited : (8)
|
References (25)
|